ArticleAmerican journal of respiratory cell and molecular biology2025
Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection.
Article in American journal of respiratory cell and molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revisiting down syndrome through the lens of interferonopathy and innate immune dysregulation.Frontiers in immunology · 2026Pooled it
- Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome.Journal of human immunity · 2026Review
- Epithelial Barrier Dysfunction in Down Syndrome: A Gateway to Chronic Lung Injury?Cell biochemistry and biophysics · 2026Review
- Selective chr21 homolog silencing reveals polymorphisms influence the epigenetic silencing and functional dosage of RWDD2B.American journal of human genetics · 2026Article
- New insight into the epidemiological trends of respiratory syncytial virus infection and the underlying anti-respiratory syncytial virus mechanisms of andrographolide: integrating Global Burden of Disease database, network pharmacological analysis, andMicrobiology spectrum · 2026Article
- Prenatal lipopolysaccharide exposure programs the early-life lung development by modulating mesenchymal fibroblasts in a time- and dose-dependent manner.BMC medicine · 2025Article
- An integrated multi-omic natural history study of human development, sexual dimorphism, and the effects of trisomy 21.Nature communications · 2025Article
- Multimodal cell death drives the immunopathogenesis of RSV infection.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Trisomy of chromosome 21 (TS21), also known as Down syndrome (DS), increases pediatric mortality risk due to respiratory syncytial virus (RSV) by ninefold. However, the underlying immunological basis remains unclear. To define the biological implications of TS21 in airway epithelial cells (AECs), the primary site of respiratory virus entry and host defense, in this study we investigated RSV-induced responses in primary nasal AECs from pediatric donors of euploid and trisomic cells. We used comprehensive approaches to assess baseline IFN-JAK-STAT signaling; viral infectivity; and the production of Type III IFN/λ1, proinflammatory cytokines, and chemokines before and after RSV exposure. TS21 AECs exhibited baseline hyperactive IFN-JAK-STAT signaling and reduced RSV infectivity but also showed impaired Type III IFN responses during viral infection. Furthermore, TS21 AECs demonstrated a robust proinflammatory state, with upregulated leukocyte/neutrophil chemotaxis pathways and heightened CXCL5/CXCL10 production before and after RSV exposure. This pattern was recapitulated in infants with DS who had severe viral bronchiolitis, exhibiting a dysregulated airway immune response characterized by diminished Type III IFN and excessive CXCL5/CXCL10 production. Our results suggest that RSV severity in DS is not due to enhanced viral infectivity but, rather, to dysregulated airway proinflammatory responses, offering new therapeutic opportunities to mitigate the severity of RSV infection in children with DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.